Arca Biopharma Inc (ABIO) 3.10 $ABIO Global Mucositis

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arca Biopharma Inc (ABIO) 3.10 $ABIO

Global Mucositis Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Cleveland BioLabs, Acta Dental, ARCA Biopharma - Research and Markets
BusinessWire - Fri Jun 10, 10:47AM CDT
Research and Markets has announced the addition of the "Mucositis Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
ABIO: 3.10 (+0.02), CBLI: 2.48 (+0.01)

ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Wed May 11, 3:30PM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended March 31, 2016, and provided a business update.
ABIO: 3.10 (+0.02)

ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial
BusinessWire - Mon Apr 18, 8:00AM CDT
--Outcome of Interim Efficacy Analysis of Data from Approximately 150 Patients Anticipated in the Second Quarter of 2017
ABIO: 3.10 (+0.02)

ARCA biopharma Announces Fiscal Year 2015 Financial Results and Provides Business Update
BusinessWire - Thu Mar 17, 3:30PM CDT
--GENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation
ABIO: 3.10 (+0.02)

Applying Lessons from KBIO
ACCESSWIRE - Tue Dec 08, 8:01AM CST
LAS VEGAS, NV / ACCESSWIRE / December 8, 2015 / KaleBios Pharmaceuticals shares have gained 1,279% this month. KaloBios has been surging since Shkreli bought a 70% stake in the company, rescuing it from insolvency. Chief Executive Officer Martin Shkreli has been pushing all the right buttons since taking charge of the company early in November, including Friday's announcement that the company will no longer lend stock to people looking to short sell it.
ABIO: 3.10 (+0.02)

2 Micro-Cap Opportunities in Atrial Fibrillation
ACCESSWIRE - Mon Nov 30, 8:38AM CST
REDONDO BEACH, CA / ACCESSWIRE / November 30, 2015 / Atrial fibrillation - or A-fib - is the most common cardiac arrhythmia, affecting roughly five million Americans, according to the American Journal of Cardiology. When the heart's upper two chambers - known as the atria - become irregular, blood pools in the chambers and predisposes a person to the formation of clots that may cause a stroke. A-fib is particularly dangerous for patients that have experienced or are experiencing cardiac trauma.
CRME: 3.13 (unch), ISIS: 57.56 (-0.28), MDT: 88.06 (+0.43), GILD: 80.46 (+0.99), MRK: 58.66 (unch), ABIO: 3.10 (+0.02), LH: 139.63 (+0.07)

Biotechs Under 20 Dollars Poised to Breakout
ACCESSWIRE - Mon Nov 23, 2:08PM CST
LAS VEGAS, NV / ACCESSWIRE / November 23, 2015 / According to Global Analyst Reports, the world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by 2015.
ABIO: 3.10 (+0.02)

ARCA biopharma to Present at the 27th Annual Piper Jaffray Healthcare Conference
BusinessWire - Thu Nov 19, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it will make a presentation at the 27th Annual Piper Jaffray Healthcare Conference.
ABIO: 3.10 (+0.02)

2 Important Takeaways from ARCA Biopharma's Q3 Results
ACCESSWIRE - Wed Nov 18, 8:42AM CST
REDONDO BEACH, CA / ACCESSWIRE / November 18, 2015 / ARCA biopharma (NASDAQ: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, recently announced its third quarter financial results and provided a business update. While the results were largely in-line with expectations, there were two key takeaways that shareholders and potential investors should note - its $41.5 million cash runway and the successful rollout of its revised trial protocols.
CYTK: 11.49 (+0.37), CRME: 3.13 (unch), ABIO: 3.10 (+0.02)

ARCA biopharma Announces Third Quarter 2015 Financial Results and Provides Business Update
BusinessWire - Thu Nov 12, 3:30PM CST
--GENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation
ABIO: 3.10 (+0.02)

ARCA biopharma CEO Michael Bristow to Present in Two Sessions at the American Heart Association Scientific Sessions 2015
BusinessWire - Thu Nov 05, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its President and CEO, Michael R. Bristow, M.D., Ph.D., will give two invited presentations at the American Heart Association Scientific Sessions 2015 (http://my.americanheart.org/professional/Sessions/ScientificSessions/Scientific-Sessions_UCM_316900_SubHomePage.jsp) being held November 7-11, 2015 in Orlando, Florida.
ABIO: 3.10 (+0.02)

Biotech Pullback: Look to Targeted Therapy Companies
ACCESSWIRE - Mon Oct 19, 8:28AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 19, 2015 / It's with good reason that there is a growing choir of voices heralding the science of targeted therapies as innovative approaches to improving medical care. Advancements in biology and technology underscore discovering specific receptors in cells that can be targeted for meaningful benefits in hard to treat diseases and conditions. There is also a significant diagnostic component in identifying which patients may benefit from certain therapies, while giving direction to avoid other treatments that likely would be ineffective. Combined, these streamline the treatment process and improve outcomes, equating to better quality of life for patients and a quantifiable savings to overburdened healthcare systems.
LOXO: 25.69 (-0.03), MDT: 88.06 (+0.43), FMI: 23.72 (+0.35), GILD: 80.46 (+0.99), LH: 139.63 (+0.07), ABIO: 3.10 (+0.02), SNY: 42.49 (-0.14), CLBS: 5.70 (+0.16)

ARCA biopharma (ABIO): Leveraging Genetic Targeting to Better Treat Cardiovascular Disease
ACCESSWIRE - Tue Sep 15, 10:20AM CDT
REDONDO BEACH, CA / ACCESSWIRE / September 15, 2015 / Cardiovascular disease is responsible for one-in-four deaths each year in the United States, or roughly 610,000 deaths each year, making it the leading cause of death in both men and women, according to the Centers for Disease Control. Despite causing more deaths than cancer each year, many cardiovascular drugs are based on loose associations rather than the precision genetic targeting that underlies many oncology drugs.
CYTK: 11.49 (+0.37), BSX: 24.43 (+0.15), MDT: 88.06 (+0.43), AZN: 33.84 (-0.30), PFE: 37.31 (+0.42), LH: 139.63 (+0.07), ABIO: 3.10 (+0.02), BMY: 76.19 (+1.38)

Gencaro(TM) Potential Efficacy Preventing Atrial Flutter in Heart Failure Paper to Be Presented at 2015 HFSA Annual Scientific Meeting
BusinessWire - Wed Sep 09, 8:00AM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper "Bucindolol Prevents Atrial Flutter via the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism" will be presented at the 19th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) to be held in Washington, D.C. September 26-29, 2015. The paper was recently published in the Journal of Cardiac Failure [http://www.onlinejcf.com/article/S1071-9164(15)00366-8/fulltext], the official journal of the Heart Failure Society of America and the Japanese Heart Failure Society. The lead author on the paper is cardiologist-electrophysiologist Ryan G. Aleong of the University of Colorado, Anschutz Medical Campus, and a co-author on the paper is Dr. Michael R. Bristow, the Company's Chief Executive Officer.
ABIO: 3.10 (+0.02)

ARCA biopharma Announces Second Quarter 2015 Operating Results and Provides Update on Recent Accomplishments
BusinessWire - Tue Aug 11, 3:00PM CDT
--Phase 2B of GENETIC-AF Projected to Complete Enrollment by Year-End 2016
ABIO: 3.10 (+0.02)

Nutritional Supplement Industry Flexes its Muscles as Natural & Pharmaceutical Supplement Products Continue to Hit the Market - Company Prepares for Strong Revenue Growth in 2nd Half of 2015
PR Newswire - Mon Jun 29, 9:27AM CDT
One of the fastest growing industries in the world is the nutritional supplement group, or more broadly known as Vitamins, Minerals and Supplements. It is projected that the industry may top $60 billion in 2021 according to the Nutritional Business Journal. Nutritional Supplement Companies, Retailers and Pharmaceutical Operations in focus today are Axxess Pharma Inc. (OTC: AXXE), Progressive Care Inc. (OTC: RXMD), USANA Health Sciences Inc. (NYSE: USNA), GNC Holdings Inc. (NYSE: GNC) and ARCA biopharma, Inc. (NASDAQ: ABIO)
OPK: 10.07 (+0.12), WWE: 19.40 (-0.35), GNC: 19.97 (-0.44), ABIO: 3.10 (+0.02), USNA: 137.16 (-0.16), RAD: 7.02 (+0.02)

ARCA biopharma raises USD34m in net proceeds from private placement
M2 - Thu Jun 18, 3:05AM CDT
Biopharmaceutical company ARCA biopharma (Nasdaq:ABIO) stated on Wednesday the sale of 42m units in a private placement financing with a select group of institutional investors.
ABIO: 3.10 (+0.02)

ARCA biopharma Announces $37 Million Private Placement
BusinessWire - Thu Jun 11, 7:50AM CDT
--Bucindolol potentially the first genetically-targeted atrial fibrillation prevention treatment
ABIO: 3.10 (+0.02)

BioPharmas are running the FDA Fast Track to Success
M2 - Wed Apr 22, 4:06AM CDT
Biopharma listings tend to reward investors early and often. One of my favorite plays in this sector is the 505(b)(2), an FDA provision that's best known as the fast track announcement. Since these announcements are often made before the street is familiar with the company, or the developmental treatment, the biopharma premium is not priced into the listings. Fast Track designation may be awarded to medicines that are intended to treat a serious or life-threatening disease, or condition, and demonstrate the potential to address unmet medical needs. In addition to reducing the development and approval timeline, the provision can also reduce the financial outlay needed to commercialize the respective products.
HZNP: 18.89 (-0.40), ABIO: 3.10 (+0.02), ORPN: 1.62 (-0.10), DYAX: 38.04 (-0.37)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Luxury's €1.5 Trillion Market Has Moved to Memories

Updated Category News Views 93

A €1.5 trillion market that cannot grow much is still a market worth fighting over, but luxury's old playbook is looking awfully tired. Bain's 2026 view is for global luxury spending to land somewhere between flat and up 2% at constant exchange rates versus 2025. That is stability, not a victory parade. Yet the total market remains 16% to 22% above 2019 levels, and the...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 141

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 116

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 21

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 184

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 112

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 107

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 75

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 90

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading

Top 5 Most Recently Viewed Articles

Venus Concept Strengthens Financial Position with Debt Exchange

Updated Category News Views 173

Venus Concept Optimizes Capital Structure through Debt Exchange Venus Concept Inc. is making waves in the medical aesthetic technology industry with its recent strategic financial decision. The company, known for its innovative solutions, has successfully exchanged $11 million worth of subordinated convertible notes for 379,311 shares of Series Y preferred stock. This...

Continue Reading
Understanding the Recent Decline of Gentex Corporation Stock

Updated Category News Views 284

Why Is Gentex Corporation Stock Down? Gentex Corporation (NASDAQ:GNTX) shares have recently faced a decline after revealing third-quarter earnings that fell short of expectations. The drop can be largely attributed to lower-than-expected earnings per share (EPS) and sales figures. Quarterly Earnings Performance For the third quarter, Gentex reported adjusted earnings of...

Continue Reading
Elliott Pressures Northern Star: Board Shake-Up Needed

Updated Category News Views 59

Reckoning Time for Northern Star Resources Well, it's about time someone rattled the cage at Northern Star. Elliott Management, never one to sit on its laurels, is clapping back at the board with a stern letter, raising eyebrows and hopes for a shake-up. They're putting their 5.6% stake to work, backing their talk with a lineup of heavyweight board candidates. The message...

Continue Reading
CBD's Role in Supporting World Cup Soccer Players

Updated Category News Views 60

World Cup Sparks Focus on Player Recovery An event like the FIFA World Cup doesn't just put its spotlight on dazzling goals and nail-biting penalty shootouts; it throws the grueling demands placed on players into sharp relief. With fixtures spread across sprawling global schedules, these athletes barely get time to breathe between matches. Rest Rules Let Players Recharge...

Continue Reading
Middlefield Canadian Income PCC: Major Holdings Announcement

Updated Category News Views 185

Overview of Middlefield Canadian Income PCC Holdings Middlefield Canadian Income PCC is actively engaged in managing major holdings and ensuring transparency in its share structure. The company recently issued a comprehensive notification, detailing the current shareholding status and changes in voting rights, importantly reflecting the interests of its shareholders....

Continue Reading